Isolation and characterization of a cDNA clone for the CCAAT transcription factor EFIA reveals a novel structural motif

Enhancer factor I (EFI) is a trans-acting factor which binds to the Rous sarcoma virus long terminal repeat enhancer and promoter at two inverted CCAAT-box motifs. We demonstrate that two forms of EFI DNA binding activity exist in nuclear extracts of avian cells. One form requires two heterologous components (EFIA)(EFIB) for high affinity, specific DNA binding activity, whereas a second form is not dependent on EFIB for binding and may be composed solely of EFIA, perhaps as a multimer. Both forms give rise to the same mobility shift in gel retardation assays, but the two forms can be separated chromatographically under buffer conditions which stabilize the two DNA binding activities. A cDNA for EFIA has been isolated from a rat liver cDNA expression library. The 1489-base pair EFIA cDNA encodes a 322-amino acid protein which is nearly identical to two previously described human DNA binding proteins. These are dbpB, a DNA binding protein of unknown specificity which binds to the epidermal growth factor receptor enhancer and c-erbB-2 gene promoter (Sakura, H., Maekawa, T., Imamoto, F., Yasuda, K., and Ishii, S. (1988) Gene (Amst.) 73, 499-507), and YB-1, a protein which recognizes the Y-box (inverted CCAAT motif) of the HLA-DR alpha chain gene (Didier, D. K., Schiffenbauer, J., Woulfe, S. L., Zacheis, M., and Schwartz, B. D. (1988) Proc. Natl. Acad. Sci. U. S. A. 85, 7322-7326). EFIA/dbpB/YB-1 share a highly conserved region of 100 amino acids with dbpA, another protein identified by Sakura et al. (1988) which binds to the epidermal growth factor receptor enhancer and c-erbB-2 gene promoter, and with two Xenopus CCAAT binding proteins, FRG Y1 and FRG Y2 (Tafuri, S. R., and Wolffe, A. P. (1990) Proc. Natl. Acad. Sci. U. S. A., in press). This highly conserved domain among all six proteins is presumed to represent or contain a DNA binding domain for the CCAAT motif. In addition, we note that the EFIA/dbpB/YB-1 polypeptide contains a novel arrangement of alternating clusters of positively and negatively charged amino acids not yet reported for any trans-acting factor. The functional significance of this novel structural motif, which is also conserved in dbpA, FRG Y1, and FRG Y2, will be discussed.     

Y-box结合蛋白功能及对肿瘤发生的影响

Y-box结合蛋白家族成员是一类高度保守的顺式作用元件, 广泛存在于原核及真核生物细胞中。它是一种多功能蛋白, 与转录调节、翻译调控、mRNA选择性剪接、DNA的修复、细胞增殖和再生等有关。Y-box结合蛋白的氨基酸序列包含3个结构域: 氨基酸N末端, 亲水结构域C末端, 冷休克结构域(cold shock domain CSD), 保守的冷休克结构域决定了Y-box结合蛋白的大部分功能。最近研究发现, 定位于细胞核中的YB-1蛋白在局部晚期非小细胞肺癌的预防上可作为新的靶位点, YB-1蛋白还可通过对抑癌基因p53启动子抑制起负调控作用, 此外, YB-1蛋白在PI3K/Akt信号通路中也起到重要的作用, 这些研究都为肿瘤的治疗提供了新的线索和启示。文章就Y-box结合蛋白功能及其对肿瘤发生的影响等方面进行概述。     

人U6基因POI Ⅲ启动子表达反义VEGF cDNA抑制SMMC-7721肝癌细胞VEGF表达的观察

 由 RNA聚合酶启动子在细胞内转录高浓度反义 RNA是抑制靶蛋白的一种有效手段 ,有报道 POI 启动子转录小分子 RNA存在效率不高 ,带有较多的非特异性序列等缺点 ,为了克服这些问题 ,表达反义 VEGF RNA的人 U6基因表达盒对人肝癌细胞株 SMMC- 772 1 VEGF表达的抑制作用进行了研究 .首先 PCR扩增 2 0 0 bp VEGF c DNA以正、反向插入人 U6 sn RNA.通过测序证实反向插入的正确性 .采用细胞原位杂交 ,RNA酶保护分析 ,Northern印迹来证实反义 RNA表达的情况 ,利用 RT- PCR方法研究了其对人肝癌细胞株 SMMC- 772 1 VEGF表达的抑制效果 .细胞原位杂交结果显示 U6启动子转录产物主要分布于细胞核内 ,细胞浆内亦有表达 ,RNA酶保护分析显示 U6基因 POI 启动子能高表达所需大小反义 RNA,Northern印迹结果显示脂质体 lipo-fectamine介导含 U6基因 POI 启动子的质粒转染人肝癌细胞株 SMMC- 772 1后 1 2 h即有表达且可持续表达 6 d. RT- PCR证实 U6基因 POI 启动子转录的反义 VEGF RNA能有效抑制SMMC- 772 1细胞 VEGF的 m RNA表达 .已有的研究结果揭示 POI 启动子是反义基因治疗中一种好的选择     

YB-1 binds to the MMP-13 promoter sequence and represses MMP-13 transactivation via the AP-1 site

Matrix metalloproteinases (MMPs) are key enzymes that implement degradation of the extracellular matrix during cellular invasion in development, tissue remodeling, and pathogenic disease states. MMP-13 has pivotal roles in the pathogenesis of invasive cancers and arthritis. Here we report the identification of Y-box binding protein-1 (YB-1) as a new repressor of MMP-13 transactivation. YB-1 binds in vitro in DNA affinity chromatography to the activator protein-1 (AP-1) DNA sequence within the MMP-13 promoter. Chromatin immunoprecipitation assays reveal that YB-1 binds in living cells to the MMP-13 gene promoter to a region of the MMP-13 promoter containing the AP-1 site. YB-1 represses tumor promoter-induced MMP-13 promoter transactivation at the AP-1 site. This is the first report demonstrating YB-1 binding in vitro and in living cells to a mammalian AP-1 target gene, and the first report of YB-1 regulation of the MMP-13 promoter.